Immunosuppression on the Horizon

Heart Failure Clinics

Volumn 3, Issue 1, 2007, Pages 43-49

  Eisen, Howard J ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CREATINE; CYCLOSPORIN A; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN;

BACTERIAL INFECTION; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CREATININE CLEARANCE; DRUG DOSE REDUCTION; DRUG MECHANISM; GRAFT RECIPIENT; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVASCULAR ULTRASOUND; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; CALCINEURIN; CYCLOSPORINE; GRAFT SURVIVAL; HEART FAILURE, CONGESTIVE; HEART TRANSPLANTATION; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; JANUS KINASE 3; KIDNEY FAILURE, CHRONIC; PROGNOSIS; PROTEIN KINASES; SIROLIMUS; TACROLIMUS;

EID: 34249696032     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2007.03.002     Document Type: Review

References (47)

1. Taylor D.O., Edwards L.B., Boucek M.M., et al. International Society for Heart and Lung Transplantation. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult heart transplantation report-2006. J Heart Lung Transplant 25 (2006) 869-79
2. Taylor D.O., Edwards L.B., Boucek M.M., et al. Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult heart transplant report-2005. J Heart Lung Transplant 24 (2005) 945-955
3. Ojo A.O., Held P.J., Port F.K., et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 349 10 (2003) 931-940
4. Cole O.J., Shehata M., and Rigg K.M. Effect of SDZ RAD on transplant arteriosclerosis in the rat aortic model. Transplant Proc 30 (1998) 2200-2203
5. Schuurman H.J., Pally C., Weckbecker G., et al. SDZ RAD inhibits cold ischemia-induced vascular remodeling. Transplant Proc 31 (1999) 1024-1025
6. Nishimura T., Faul J., Berry G.J., et al. 40-0-(2-hydroxylethyl)-rapamycin attenuates pulmonary arterial hypertension and neointimal formation in rats. Am J Respir Crit Care Med 163 (2001) 498-502
7. Schuler W., Sedrani R., Cottens S., et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 64 (1997) 36-42
8. Schuurman H.J., Cottens S., Fuchs S., et al. SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. Transplantation 64 (1997) 32-35
9. Hausen B., Boeke K., Berry G., et al. Suppression of acute rejection in allogeneic rat lung transplantation: a study of the efficacy and pharmacokinetics of rapamycin derivative (SDZ RAD) used alone and in combination with a microemulsion formulation of cyclosporine. J Heart Lung Transplant 18 (1999) 150-159
10. Keogh A., Richardson R.M., Rugyrok P., et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years-a randomized clinical trial. Circulation 110 (2004) 2694-2700
11. Eisen H.J., Tuzcu E.M., Dorent R., et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac transplant recipients. N Engl J Med 349 (2003) 847-858
12. Hiatt W.R., and Nissen S.E. Cardiovascular and Renal Drugs Advisory Committee, US Food and Drug Administration. New drug application 21-628, Certican (everolimus), for the proposed indication of prophylaxis of rejection in heart transplantation: report from the Cardiovascular and Renal Drugs Advisory Committee, US Food and Drug Administration, November 16, 2005, Rockville, MD. Circulation 113 (2006) e394-e395
13. Lehmkuhl H., and Hetaer R. Clinical experience with Certican (everolimus) in de novo heart transplant patients-Deutsches Herzzentrum Berlin. J Heart Lung Transplant 24 Suppl 4 (2005) S201-S205
14. Kuppahally S., Al-Khaldi A., Weisshaar D., et al. Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients. Am J Transplant 6 5 Pt 1 (2006) 986-992
15. Mancini D., Pinney S., Burkhoff D., et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 108 (2003) 48-53
16. Koehl G.E., Andrassy J., Guba M., et al. Rapamycin protects allografts while simultaneously attacking tumors in immunosuppressed mice. Transplantation 77 (2004) 1319-1326
17. Majewski M., Korecka M., Joergensen J., et al. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from post-transplant lymphoproliferative disorder at allograft protecting doses. Transplantation 75 (2003) 1710-1717
18. Rubio-Viqueira B., and Hidalgo M. Targeting mTOR for cancer treatment. Adv Exp Med Biol 587 (2006) 309-27
19. Motzer R.J., and Bukowski R.M. Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 24 35 (2006) 5601-5608
20. Stallone G., Schena A., Infante B., et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 352 (2005) 1317-1323
21. Kauffman H.M., Cherikh W.S., Cheng Y., et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 80 7 (2005) 883-889
22. Kushwaha S.S., Khalpey Z., Frantz R.P., et al. Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity. J Heart Lung Transplant 24 (2005) 2129-2136
23. Groetzner J., Meiser B., Landwehr P., et al. Mycophenolate mofetil and sirolimus as calcineurin inhibitor free immunosuppression for late cardiac-transplant recipients with chronic renal failure. Transplantation 77 (2004) 568-574
24. Lyster H., Panicker G., Leaver N., et al. Initial experience with sirolimus and mycophenolate mofetil for renal rescue from cyclosporine nephrotoxicity after heart transplantation. Transplant Proc 36 (2004) 3167-3170
25. Moloney E.D., O'Mahony U., Kirwan M., et al. Pharmacokinetics of sirolimus in heart transplant recipients with chronic renal impairment. Transplant Proc 36 (2004) 1547-1550
26. Liu J., Farmer Jr. J.D., Lane W.S., et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 66 (1991) 807-815
27. Mentzer Jr. R.M., Jahania M.S., and Lasley R.D. Tacrolimus as a rescue immunosuppressant after heart and lung transplantation. The U.S. Multicenter FK506 Study Group. Transplantation 65 (1998) 109-113
28. Taylor D.O., Barr M.L., Radovancevic B., et al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant 18 (1999) 336-345
29. Kobashigawa J.A., Miller L.W., Russell S.D., et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 6 (2006) 1377-1386
30. Lubitz S.A., Baran D.A., Alwarshetty M.M., et al. Long-term results of tacrolimus monotherapy in cardiac transplant recipients. J Heart Lung Transplant 25 (2006) 699-706
31. Calne S.R. The use of alemtuzumab (Campath 1H) in organ transplant recipients. Curr Opin Organ Transplant 10 (2005) 261-264
32. Starzl T.E., Maurase N., Abut-Ellmagd K., et al. Tolerogenic immunosuppression for organ transplantation. Lancet 361 (2003) 1502-1510
33. Kaufman D.B., Leventhal J.R., Axelrod D., et al. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction long-term result. Am J Transplant 5 5 (2006) 2539-2548
34. Kaufman D.B., Leventhal J.R., Gallon L.G., et al. Alemtuzumab induction and prednisone-free immunotherapy in simultaneous pancreas-kidney transplantation comparison with rabbit antithymocyte globulin induction-long-term results. [abstract 431]. Am J Transplant 6 (2006) 331-339
35. Pham S.M., Jimenez J., Bednar B.M., et al. Campath in clinical heart transplantation. J Heart Lung Transplant 25 (2006) S126 [abstract]
36. Kokko K.E., Newell K.A., Pearson T.C., et al. Enhanced immunosuppression induced by targeted mutation of cytotoxic T lymphocyte antigen-4 immunoglobulin. Curr Opin Organ Transplant 10 (2006) 265-269
37. Walunas T.L., Lenschow D.J., Bakker C.Y., et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1 (1994) 405-413
38. Larsen C.P., Pearson T.C., Adams A.B., et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-lg with potent immunosuppressive properties. Am J Transplant 5 (2005) 443-453
39. Larsen C.P., Knechtle S.J., Adams A., et al. A new look at T cell costimulation: a therapeutic strategy for long-term maintenance immunosuppression. Am J Transplant 6 (2006) 876-883
40. Yamaoka K., Saharinen P., Pesu M., et al. The Janus kinases (Jaks). Genome Biol 5 (2004) 253
41. Borie D.C., Starr R., Hendry S., et al. Janus kinase 3 inhibition for immunosuppression: getting closer to the starting line. Curr Opin Organ Transplant 10 (2005) 273-278
42. Levy D.E., and Darnell Jr. J.E. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 3 (2002) 651-662
43. Buckley R.H. Advances in the understanding and treatment of human severe combined immunodeficiency. Immunol Res 22 (2000) 237-251
44. Changelian P.S., Flanagan M.E., Ball D.J., et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302 (2003) 875-878
45. Borie D., Hausen B., Larson M., et al. A life-supporting technique of rental allo-transplantation in Macaca fascicularis to evaluate novel immunosuppressive drugs in nonhuman primates. J Surg Res 107 (2002) 64-74
46. Borie D.C., Changelian P.S., Larson M.J., et al. Immunosuppression by the JAK3 inhibitor CP-690,550 delays rejection and significantly prolongs kidney allograft survival in nonhuman primates. Transplantation 79 (2005) 791-801
47. Rousvoal G., Si M.S., Lau M., et al. Janus kinase 3 inhibition with CP-690,550 prevents allograft vasculopathy. Am J Transplant 19 (2006) 1014-1021